The FDA petitioned a federal judge to dismiss a lawsuit from Mylan that seeks an injunction forcing the agency to deny a six-month exclusivity period for Ranbaxy Laboratories' generic version of Lipitor, Pfizer's cholesterol-lowering drug. The agency said Mylan's legal action is premature because the agency has not approved any generic Lipitor.

Related Summaries